Company Profile

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company's pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.

Employees

Sector

Biotechnology & Medical Research

More about the company

Regeneron Pharmaceuticals Completes Acquisition of Decibel Therapeutics	25/09/23	MT
Decibel Therapeutics, Inc. Announces Board Changes	25/09/23	CI
Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index	25/09/23	CI
Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from S&P TMI Index	25/09/23	CI
Regeneron Pharmaceuticals, Inc. acquired remaining 91.65% stake in Decibel Therapeutics, Inc. from a group of shareholders.	24/09/23	CI
Decibel Therapeutics' Gene Therapy Candidate Granted US FDA's Fast-Track Designation	25/08/23	MT
Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO	25/08/23	CI
Decibel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
North American Morning Briefing : Stock Futures -2-	11/08/23	DJ
Global markets live: Allianz, Generali, Sony, Disney, Alibaba...	10/08/23
Baird Downgrades Decibel Therapeutics to Neutral From Outperform, Adjusts Price Target to $5.25 From $21	10/08/23	MT
North American Morning Briefing : Attention Turns -2-	10/08/23	DJ
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	09/08/23	MT

Baird Downgrades Decibel Therapeutics to Neutral From Outperform, Adjusts Price Target to $5.25 From $21	10/08/23	MT
HC Wainwright Downgrades Decibel Therapeutics to Neutral From Buy	09/08/23	MT
SVB Securities Downgrades Decibel Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2 From $7	15/03/23	MT
SVB Securities Adjusts Price Target on Decibel Therapeutics to $7 From $10, Maintains Outperform Rating	23/01/23	MT
Citigroup Adjusts Price Target on Decibel Therapeutics to $10 From $12, Maintains Buy Rating	10/11/22	MT

Decibel Therapeutics : Acquisition/Asset Disposal - Form 8-K	25/09/23	PU
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX	05/09/23	BU
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update	14/08/23	AQ
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX	12/08/23	BU
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update	11/08/23	GL

EN DIRECTO DESDE LOS MERCADOS: Rheinmetall, Allianz, Novo Nordisk, Walt Disney, Sony, KBC, Siemens, Meta, Ahold...	10/08/23
Tout augmente, ma pauvre dame !	10/08/23
Bolsa de Madrid: ¡Todo en aumento, mi pobre señorita!	10/08/23
En Direct des Marchés : Alstom, Tapestry, Walt Disney, Sony, KBC, Siemens, Meta, Ahold...	10/08/23

Director	Title	Age	Since
Robert Landry DFI	Director of Finance/CFO	61	21/09/2023
Nouhad Husseini PRN	Corporate Officer/Principal	-	21/09/2023
Leonard Brooks TRE	Treasurer	-	21/09/2023

Decibel Therapeutics, Inc. Share Price

Equities

DBTX

US24343R1068

Biotechnology & Medical Research

Latest news: Decibel Therapeutics, Inc.

Analysts' recommendations: Decibel Therapeutics, Inc.

Press Releases: Decibel Therapeutics, Inc.

News in other languages: Decibel Therapeutics, Inc.

Managers and Directors: Decibel Therapeutics, Inc.

Other Biotechnology & Medical Research

Company Profile

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
LONZA GROUP AG	+0.53%	+5.40%	+51.89%	-11.83%	44.81B
IQVIA HOLDINGS INC.	-0.15%	-3.56%	-8.37%	-19.25%	35.82B
CELLTRION, INC.	+0.39%	-1.69%	+7.80%	+19.59%	26.64B
ICON PUBLIC LIMITED COMPANY	-2.15%	-9.12%	-23.68%	-22.59%	16.36B
UNITED THERAPEUTICS CORPORATION	-2.04%	-1.09%	+64.77%	+79.49%	16.02B
MODERNA, INC.	+0.89%	-3.10%	-65.84%	-79.67%	13.11B
BIO-TECHNE CORPORATION	-0.35%	-0.77%	+7.84%	-19.59%	12.05B
MEDPACE HOLDINGS, INC.	+0.16%	-4.16%	+14.09%	+99.18%	10.46B
QIAGEN N.V.	+0.22%	0.00%	-1.13%	-9.99%	10.22B
Average	-0.28%	-3.25%	+5.26%	+3.93%	20.61B
Weighted average by Cap.	-0.15%	-2.18%	+12.14%	-0.74%